OPEN CLINICAL TRIALS

NCT05633654

GileadUS-595-6184ASCENT 05

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

NCT04873362

GenentechWO42633ASTEFANIA

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT05296798

GenentechWO43571heredERA

A Phase III, 2 Arm, Randomized, Open-Label, Multicenter, Registrational Study Evaluating the Efficacy and Safety of Giredestrant in Combination with Phesgo Versus Phesgo (+/- Endocrine Therapy) After Induction Chemotherapy (Phesgo+Taxane) in Patients with Previously Untreated HER2-Positive, Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

NCT04964934

AstraZenecaD8534C00001SERENA-6

A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study

NCT05501886

Celcuity CELC-G-301VIKTORIA-1

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

NCT05057494

AstraZenecaD8220C00027MAJIC

MAJIC: A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05254743

Loxo OncologyLoxo-BTK-20030BRUIN-CLL-314

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

NCT04965493

Loxo OncologyLOXO-BTK-20022BRUIN CLL-322

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

NCT03833154

AstraZenecaD9103C00001PACIFIC-4

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation

NCT05555732

Daiichi SankyoDS1062-A-U303TROPION-Lung07

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

NCT04042701

Daiichi SankyoDS8201-A-U106

A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, For Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)

NCT04613596

Mirati TherapeuticsMRTX- 849-007KRYSTAL-7

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

NCT04685135

Mirati TherapeuticsMRTX 849-012KRYSTAL-12

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

NCT04919811

AnHeart TherapeuticsTRUST-II

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors

NCT05353257

Shanghai Henlius BiotechHLX10-020-SCLC302

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05207670

GenentechML43389MorningSun

An open-label, multicenter, phase II trial evaluating the safety, efficacy, and pharmacokinetics of subcutaneous mosunetuzumab monotherapy in patients with select B-cell malignancies

NCT04224493

Epizyme EZH-302

A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituxumab in Subjects with Relapsed/Refractory Follicular Lymphoma

NCT04270409

Sanofi EFC15992

A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma

NCT03110822

Oncotherapeutics I-RUX-15-04

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

NCT01688011

Celgene Connect Myeloid

Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

NCT04797780

Syros SY-1425-301SELECT MDS-1

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)

NCT04720157

Novartis CAAA617C12301PSMAddition

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT02912949

MCLA-128-CL01 Merus

A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

NCT04985604

DOT TherapeuticsDay 101-102BFIRELIGHT-01

A Phase 1b/2, Subprotocol of Day101 in Combination with Pimasertib for Patients with Recurrent, Progressive, or Refractory Solid Tumors and MAPK Pathway Aberrations

NCT04985604

DOT TherapeuticsDay 101-102AFIRELIGHT-01

A Phase 2, Subprotocol of Day101 Monotherapy for Patients with Recurrent, Progressive, or Refractory Solid Tumors with MAPK Pathway Aberrations

NCT04919811

AnHeart Therapeutics TRUST-II

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors

NCT05103358

AadiTSC-007PRECISION-1

A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.

CSNF is part of The TIME Trial Program, a just-in-time network of providers that supports rapid patient identification, site activation, and enrollment of select clinical trials. Building off of existing relationships with a large network of community hospitals and practices, TIME activates clinical trials at pre-qualified sites in its network in an average of 10 days, bringing the very best clinical trials to community centric parts of this country and giving access to thousands of patients that have historically been denied novel therapeutics. As part of The TIME Trial Network, CSNF has access to the biggest marketplace of trials that can be quickly initiated when there is a patient on-site that is ready to enroll. The program's just-in-time model allows for both sites and sponsors to locate extremely rare patients and then open a trial specifically on that patient’s behalf in a fraction of the time it typically takes.